Table 4 Analysis of discordant results between APM and BMD UKMYC6 plate methodology
Drug | Total | APM | BMD | WGS | APM results supported by WGS (%) | BMD results supported by WGS (%) | |
|---|---|---|---|---|---|---|---|
S | R | ||||||
Rifampicin | 30 | S | R | 1 | 1 | 22 (73) | 8 (27) |
R | S | 7 | 21 | ||||
Isoniazid | 9 | S | R | 2 | 1 | 4 (44) | 5 (56) |
R | S | 4 | 2 | ||||
Ethambutol | 49 | S | R | 0 | 8 | 23 (47) | 26 (53) |
R | S | 18 | 23 | ||||
Ethionamide | 64 | S | R | 7 | 11 | 29 (45) | 35 (55) |
R | S | 24 | 22 | ||||
Kanamycin | 17 | S | R | 0 | 0 | 9 (53) | 8 (47) |
R | S | 8 | 9 | ||||
Levofloxacin | 10 | S | R | 1 | 2 | 6 (60) | 4 (40) |
R | S | 2 | 5 | ||||